Your browser doesn't support javascript.
loading
Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis.
Naoi, Hyogo; Suzuki, Yuzo; Mori, Kazutaka; Aono, Yuya; Kono, Masato; Hasegawa, Hirotsugu; Yokomura, Koshi; Inoue, Yusuke; Hozumi, Hironao; Karayama, Masato; Furuhashi, Kazuki; Enomoto, Noriyuki; Fujisawa, Tomoyuki; Nakamura, Yutaro; Inui, Naoki; Nakamura, Hidenori; Suda, Takafumi.
Afiliación
  • Naoi H; Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Suzuki Y; Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan yuzosuzu@hama-med.ac.jp.
  • Mori K; Department of Respiratory Medicine, Shizuoka City Shimizu Hospital, Shizuoka, Japan.
  • Aono Y; Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Kono M; Department of Respiratory Medicine, Seirei Hamamatsu Hospital, Hamamatsu, Japan.
  • Hasegawa H; Department of Respiratory Medicine, Seirei Mikatahara Hospital, Hamamatsu, Japan.
  • Yokomura K; Department of Respiratory Medicine, Seirei Mikatahara Hospital, Hamamatsu, Japan.
  • Inoue Y; Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Hozumi H; Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Karayama M; Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Furuhashi K; Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Enomoto N; Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Fujisawa T; Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Nakamura Y; Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Inui N; Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Nakamura H; Department of Respiratory Medicine, Seirei Hamamatsu Hospital, Hamamatsu, Japan.
  • Suda T; Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Thorax ; 77(7): 727-730, 2022 07.
Article en En | MEDLINE | ID: mdl-35354649
ABSTRACT
Patients with idiopathic pulmonary fibrosis (IPF) are at a high risk of lung cancer (LC). Antifibrotic therapy slows disease progression and possibly prolongs survival. However, whether antifibrotic therapy affects LC development in patients with IPF remains unknown. This multicentre retrospective study evaluated 345 patients with IPF. The incidence and prevalence of LC were significantly lower in patients with IPF receiving antifibrotic therapy than those not receiving. Subsequently, LC-related mortality was significantly lower in patients with IPF receiving antifibrotic therapy. These results suggest that antifibrotic therapy was possibly associated with a reduced risk of LC development in patients with IPF, which may be partly associated with its survival benefit.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Fibrosis Pulmonar Idiopática / Neoplasias Pulmonares Tipo de estudio: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Thorax Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Fibrosis Pulmonar Idiopática / Neoplasias Pulmonares Tipo de estudio: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Thorax Año: 2022 Tipo del documento: Article